10 of the 10 current GLP-1 labels carry a warning on kidney problems. Wegovy's label says: "There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with semaglutide."
Read from each manufacturer's FDA label on DailyMed. The newest revision saying anything on this is Aug 28, 2026.
Word for word
What each label says about kidney problems
Sentences from each label's warnings and side effect sections. Only cross-references are removed.
Wegovy · Warning: Acute Kidney Injury Due to Volume Depletion
There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with semaglutide.
The majority of the reported events occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration such as nausea, vomiting, or diarrhea.
Monitor renal function in patients reporting adverse reactions to Wegovy that could lead to volume depletion, especially during dosage initiation and escalation of Wegovy.
Acute kidney injury occurred in clinical trials for weight reduction in 7 adult patients (0.4 cases per 100 patient years) receiving Wegovy versus 4 patients (0.2 cases per 100 patient years of exposure) receiving placebo.
Ozempic · Warning: Acute Kidney Injury Due to Volume Depletion
There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with semaglutide.
The majority of the reported events occurred in patients who experienced gastrointestinal reactions leading to dehydration such as nausea, vomiting, or diarrhea.
Monitor renal function in patients reporting adverse reactions to Ozempic that could lead to volume depletion, especially during dosage initiation and escalation of Ozempic.
There have been postmarketing reports of acute kidney injury in some cases requiring hemodialysis, in patients treated with semaglutide.
The majority of the reported events occurred in patients who experienced gastrointestinal reactions leading to dehydration such as nausea, vomiting, or diarrhea.
Monitor renal function in patients reporting adverse reactions to Rybelsus or Ozempic tablets that could lead to volume depletion, especially during dosage initiation and escalation of Rybelsus or Ozempic tablets.
Zepbound · Warning: Acute Kidney Injury Due to Volume Depletion
There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with GLP-1 receptor agonists, or Zepbound.
The majority of the reported events occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration such as nausea, vomiting, or diarrhea.
Monitor renal function in patients reporting adverse reactions to Zepbound that could lead to volume depletion, especially during dosage initiation and escalation of Zepbound.
In a pool of Study 1 and 2, acute kidney injury was reported in 0.5% of Zepbound-treated patients compared to 0.2% of placebo-treated patients.
Mounjaro · Warning: Acute Kidney Injury Due to Volume Depletion
There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with GLP-1 receptor agonists, or Mounjaro.
The majority of the reported events occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration such as nausea, vomiting, or diarrhea.
Monitor renal function in patients reporting adverse reactions to Mounjaro that could lead to volume depletion, especially during dosage initiation and escalation of Mounjaro.
Foundayo · Warning: Acute Kidney Injury Due to Volume Depletion
There have been reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with GLP-1 receptor agonists or Foundayo.
The majority of the reported events occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration such as nausea, vomiting, or diarrhea.
Monitor renal function in patients reporting adverse reactions to Foundayo that could lead to volume depletion, especially during dosage initiation and escalation of Foundayo.
In a pool of Trials 1 and 2, acute kidney injury was reported in 0.2% of Foundayo-treated patients compared to 0.05% of placebo-treated patients.
Trulicity · Warning: Acute Kidney Injury Due to Volume Depletion
There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with GLP-1 receptor agonists, including Trulicity.
The majority of the reported events occurred in patients who experienced gastrointestinal reactions leading to dehydration such as nausea, vomiting, or diarrhea.
Monitor renal function in patients reporting adverse reactions to Trulicity that could lead to volume depletion, especially during dosage initiation and escalation of Trulicity.
Saxenda · Warning: Acute Kidney Injury Due to Volume Depletion
There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with liraglutide.
The majority of the reported events occurred in patients who had experienced gastrointestinal reactions leading to dehydration such as nausea, vomiting, or diarrhea.
Monitor renal function in patients reporting adverse reactions to Saxenda that could lead to volume depletion, especially during dosage initiation and escalation.
There have been reports of gastrointestinal adverse reactions, such as nausea, vomiting, and diarrhea, associated with volume depletion and renal impairment.
Victoza · Warning: Acute Kidney Injury Due to Volume Depletion
There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with Victoza.
The majority of the reported events occurred in patients who experienced gastrointestinal reactions leading to dehydration such as nausea, vomiting, or diarrhea.
Monitor renal function in patients reporting adverse reactions to Victoza that could lead to volume depletion, especially during dosage initiation and escalation of Victoza..
In one adult glycemic control trial in renal impairment patients, a mean increase of 33% for lipase and 15% for amylase from baseline was observed for Victoza-treated patients while placebo-treated patients had a mean decrease in lipase of 3% and a mean increase in amylase of 1%.
Byetta · Warning: Acute Kidney Injury Due to Volume Depletion
There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with GLP-1 receptor agonists, Byetta.
The majority of the reported events occurred in patients who experienced gastrointestinal reactions leading to dehydration such as nausea, vomiting, or diarrhea.
Monitor renal function in patients reporting adverse reactions to Byetta that could lead to volume depletion, especially during dosage initiation and escalation of Byetta.
Counts of voluntary reports from patients and doctors. They cannot show that a medicine caused anything and cannot give a rate, and a brand used by more people draws more reports.
Its FDA label: There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with semaglutide. The majority of the reported events occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration such as nausea, vomiting, or diarrhea.
Does Ozempic cause kidney problems?
Its FDA label: There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with semaglutide. The majority of the reported events occurred in patients who experienced gastrointestinal reactions leading to dehydration such as nausea, vomiting, or diarrhea.
Does Rybelsus cause kidney problems?
Its FDA label: There have been postmarketing reports of acute kidney injury in some cases requiring hemodialysis, in patients treated with semaglutide. The majority of the reported events occurred in patients who experienced gastrointestinal reactions leading to dehydration such as nausea, vomiting, or diarrhea.
Does Zepbound cause kidney problems?
Its FDA label: There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with GLP-1 receptor agonists, or Zepbound. The majority of the reported events occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration such as nausea, vomiting, or diarrhea.
Does Mounjaro cause kidney problems?
Its FDA label: There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with GLP-1 receptor agonists, or Mounjaro. The majority of the reported events occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration such as nausea, vomiting, or diarrhea.
Does Foundayo cause kidney problems?
Its FDA label: There have been reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with GLP-1 receptor agonists or Foundayo. The majority of the reported events occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration such as nausea, vomiting, or diarrhea.
Does Trulicity cause kidney problems?
Its FDA label: There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with GLP-1 receptor agonists, including Trulicity. The majority of the reported events occurred in patients who experienced gastrointestinal reactions leading to dehydration such as nausea, vomiting, or diarrhea.
Does Saxenda cause kidney problems?
Its FDA label: There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with liraglutide. The majority of the reported events occurred in patients who had experienced gastrointestinal reactions leading to dehydration such as nausea, vomiting, or diarrhea.
Does Victoza cause kidney problems?
Its FDA label: There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with Victoza. The majority of the reported events occurred in patients who experienced gastrointestinal reactions leading to dehydration such as nausea, vomiting, or diarrhea.
Trial rates describe groups, not what one person will feel. Talk to your clinician before starting, stopping or changing a medicine.
GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.